PD-1 inhibitor sintilimab treated patients with metastatic triple-negative breast cancer
PurposeTriple-negative breast cancer (TNBC) is a highly challenging subtype due to a unique tumor microenvironment. Several evidence (IMpassion130 trial and KEYNOTE-355 trial) supported the therapeutic effect of the immune checkpoint inhibitor in TNBC. However, the efficacy and safety of the PD-1 in...
| 出版年: | Frontiers in Cell and Developmental Biology |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | 論文 |
| 言語: | 英語 |
| 出版事項: |
Frontiers Media S.A.
2024-10-01
|
| 主題: | |
| オンライン･アクセス: | https://www.frontiersin.org/articles/10.3389/fcell.2024.1430310/full |